MedImmune
From Wikipedia, the free encyclopedia
MedImmune, Inc. NASDAQ: MEDI is a Maryland-based biotechnology company.
MedImmune produces Synagis, a drug for the prevention of respiratory infections in infants, that accounted for $1.06 billion of its $1.2 billion in revenue for 2005, and FluMist, a nasal spray flu vaccine introduced in 2004. Sales of FluMist have fallen short of analysts' expectations for the first two years the drug was sold. FluMist is sold in a frozen form, which is difficult for doctors to store. It is also approved only for healthy people ages 5 to 49, a significant limitation because it eliminates a significant market -- the millions of young children who find injections objectionable.
The company is conducting clinical trials for a new generation of flu vaccine, called CAIV-T. MedImmune reported a 16.6 million loss in 2005, and a $3.8 million loss the previous year for $1.14 billion in revenue.
[edit] External links
[edit] References
- Bishop, Tricia. "MedImmune loss in '05 quadruples shortfall from '04" Baltimore Sun. 3 February 2006.
- Rosenwald, Michael S. "Sales of MedImmune's Flu Vaccine Drop Sharply" Washington Post. 3 February 2006.